Radiomics analysis on FLT-PET/MRI for characterization of early treatment response in renal cell carcinoma: A proof-of-concept study

Translational Oncology

Volumn 9, Issue 2, 2016, Pages 155-162

  Antunes, Jacob ^a   Viswanath, Satish ^a   Rusu, Mirabela ^b   Valls, Laia ^c   Hoimes, Christopher ^d   Avril, Norbert ^c   Madabhushi, Anant ^a  

^a Case Western Reserve University   (United States)

^b GE GLOBAL RESEARCH   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; SUNITINIB;

ALGORITHM; ANTIANGIOGENIC THERAPY; ARTICLE; CELL PROLIFERATION; DIFFUSION COEFFICIENT; DIFFUSION WEIGHTED IMAGING; IMAGE ANALYSIS; KIDNEY CARCINOMA; MATHEMATICAL COMPUTING; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY ANALYSIS; SURVIVAL RATE; TREATMENT RESPONSE;

EID: 84963507404     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1016/j.tranon.2016.01.008     Document Type: Article

References (39)

1. De Cecco CN, Ganeshan B, Ciolina M, Rengo M, Meinel FG, Musio D, De Felice F, Raffetto N, Tombolini V, and Laghi A (2015). Texture analysis as imaging biomarker of tumoral response to neadjuvant chemoradiotherapy in rectal cancer patients studied with 3-T magnetic resonance. Invest Radiol 50(4), 239–245.
2. NCCN (2015). Clinical practice guidelines in oncology: kidney. Cancer 3.
3. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, and Silverman DH (2005). Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med 46, 945–952.
4. Murakami M, Zhao S, Zhao Y, Yu W, Fatema CN, Nishijima KI, Yamasaki M, Takiquchi M, Tamaki N, and Kuge Y (2013). Increased intratumoral fluorothymidine uptake levels following multikinase inhibitor sorafenib treatment in a human renal cell carcinoma xenograft model. Oncol Lett 6,667–672.
5. Bao X, Wang M, Zhang Y, and Zhang Y (2014). Early monitoring antiangiogenesis treatment response of sunitinib in U87MG tumor xenografft by 18F-FLT MicroPET/CT Imaging. Biomed Res Int 2014,1–9 218578.
6. Padhani AR, Liu G, Mu-Koh D, Chenevert TL, Thoeny HC, Takahara T, Dzik-Jurasz A, Ross BD, Van Cauteren M, and Collins D, et al (2009). Diffusion-weighted magnetic resonance imaging as a cancer biomarker: concensus and recommendations. Neoplasia 11, 102–125.
7. Sun YS, Zhang XP, Tang L, Ji JF, Gu J, Cai Y, and Zhang XY (2010). Locally advanced rectal carcinoma treated with preoperative chemotherapy and radiation therapy: preliminary analysis of diffusion-weighted MR imaging for early detection of tumor histopathologic downstaging. Radiology 254(1), 170–178.
8. Partovi S, Dohan A, Rubbert C, Vercher-Conejero JL, Gaeta C, Yuh R, Zipp L, Herrmann KA, Robbin MR, and Lee Z, et al (2014). Clinical oncologic applications of PET/MRI: a new horizon. Am J Nucl Med Mol Imaging 4, 202–212.
9. Eisenhuuer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, and Mooney M, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45,228–247.
10. Kang HC, Tan K, Keefe SM, Heitjan DF, Siegelman ES, Flaherty KT, O'Dwyer PJ, and Rosen MA (2013). MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. AJR Am J Roentgenol 200, 120–126.
11. Wahl RL, Jacene H, Kasamon Y, and Lodge MA (2009). From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 50(Suppl 1), 122S–150S.
12. Hee K, Lee HY, Lee KS, and Kim JH (2012). Imaging-based tumor treatment response evaluation: review of conventional, new, and emerging concepts. Korean J Radiol 13(4), 371–390.
13. Zitova B and Flusser J (2003). Image registration methods: a survey. Imag Vis Comput 21, 977–1000.
14. Palumb D, Yee B, and Madabhushi A (2011). Interplay between bias field correction, intensity standardization, and noise filtering for T2-weighted MRI. Conf Proc IEEE Eng Med Biol Soc 2011, 5080–5083.
15. Lambin P, Rios-Velazquez E, Leinjenaar R, Carvalho S, van Stiphout RG, Granton P, Zegers CM, Gillies R, Boellard R, and Dekker A, et al (2012). Radiomics: extracting more information from medical images using advanced feature analysis. Eur J Cancer 48(4), 441–446.
16. Viswanath S, Toth R, Rusu M, Sperling D, Lepor H, Futterer J, and Madabhushi A (2014). Identifying quantitative in vivo multi-parameteric MRI features for treatment related changes after laster interstitial thermal therapy of prostate cancer. Neurocomputing 144, 13–23.
17. Viswanath SE, Bloch NB, Chappelow JC, Toth R, Rofsky NM, Genega EM, Lenkinski RE, and Madabhushi A (2012). Central gland and peripheral zone prostate tumors have significantly different quantitative signatures on 3 tesla endorectal in vivo T2-weighted MR imagery. J Magn Reson Imaging 36, 213–224.
18. Ginsburh S, Rusu M, Kurhanewicz J, and Madabhushi A (2014). Computer extracted texture features on T2w MRI to predict biochemical recurrence following radiation therapy for prostate cancer. Proc SPIE Int Med Imag 9035(903509), 1–13.
19. Litjens G, Huisman H, Elliot R, Shih NN, Feldman MD, Viswanath S, Futterer JJ, Boomers JG, and Madabhushi A (2014). Quantitative identification of magnetic resonance imaging features of prostate cancer response following laser ablation and radical prostatectomy. J Med Imaging 1(3), 035001.
20. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, and Kim ST, et al (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356, 115–124.
21. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, and DePrimo SE (2006). Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24, 16–24.
22. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, and Xiong HQ, et al (2006). Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24, 2505–2512.
23. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, and Desai AA, et al (2007). Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356, 125–134.
24. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, and Massimini G, et al (2006). Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24, 25–35.
25. Chow LQ and Eckhardt SG (2007). Sunitinib: from rational design to clinical efficacy. J Clin Oncol 25, 884–896.
26. Condon BR, Patterson J, Wyper D, Jenkins A, and Hadley DM (1987). Image non-uniformity in magnetic resonance imaging: its magnitude and methods for its correction. Br J Radiol 60(709), 83–87.
27. Vovk U, Pernus F, and Likar B (2007). A review of methods for correction of intensity inhomogeneity in MRI. IEEE Trans Med Imaging 26(3), 405–421.
28. Cohen M, DuBois R, and Zeineh M (2000). Rapid and effective correction of RF inhomogeneity for high field magnetic resonance imaging. Hum Brain Mapp 10, 204–211.
29. Klein S, Staring M, Murphy K, Viergever MA, and Pluim JPW (2010). elastix: a toolbox for intensity based medical image registration. IEEE Trans Med Imaging 29(1), 96–205.
30. Nyul LG, Udupa JK, and Zhang X (2000). New variants of a method of MRI scale standardization. IEEE Trans Med Imaging 19(2), 143–150.
31. Masa-ah P and Soongsathitanon S (2010). A novel standardized uptake value (SUV) calculation of PET DICOM files using MATLAB. WSEAS Int Conf on Biomedical Electronics and Biomedical Informatics; 2010.
32. Agner SC, Soman S, Libfeld E, McDonald M, Thomas K, Englander S, Rosen MA, Chin D, Nosher J, and Madabhushi A (2010). Textural kinetics: a novel dynamic contrast-enhanced (DCE)-MRI feature for breast lesion classification. J Digit Imaging 24, 446–463.
33. Haralick RM, Shanmugam K, and Dinstein I (1973). Textural features for image classification. IEEE Trans Syst Man Cybern 3(6), 610–621.
34. Brooks FH and Grigsby PW (2014). The effect of small tumor volumes on studies of intratumoral heterogeneity of tracer uptake. J Nucl Med 55, 37–42.
35. Orlhac F, Soussan M, Maisonobe JA, Garcia CA, Vanderlinden B, and Buvat I (2014). Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med 55, 414–422.
36. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi–cancer site patient cohort. J Nucl Med 56(1), 38–44.
37. Kailath T (1967). The divergence and Bhattacharyya distance measures in signal selection. IEEE Trans Commun Technol 15(1), 52–60.
38. Valls L, Hoimes C, Sher A, Hu L, Lee Z, Muzic R, and Avril N (2014). Early response monitoring of receptor tyrosine kinase inhibitor therapy in metastatic renal cell carcinoma using [F-18]fluorothymidine-positron emission tomography-magnetic resonance. Semin Roentgenol 49(3), 238–241.
39. Lopes R, Ayache A, Makni N, Puech P, Villers A, Mordon S, and Betrouni N (2010). Prostate cancer characterization on MR images using fractal features. Med Phys 38, 83–95.